These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 27564310)

  • 1. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
    Campos CM; Caixeta A; Franken M; Bartorelli AL; Whitbourn RJ; Wu CJ; Li Paul Kao H; Rosli MA; Carrie D; De Bruyne B; Stone GW; Serruys PW; Abizaid A;
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):387-395. PubMed ID: 28471086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
    Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
    Kimura T; Kozuma K; Tanabe K; Nakamura S; Yamane M; Muramatsu T; Saito S; Yajima J; Hagiwara N; Mitsudo K; Popma JJ; Serruys PW; Onuma Y; Ying S; Cao S; Staehr P; Cheong WF; Kusano H; Stone GW;
    Eur Heart J; 2015 Dec; 36(47):3332-42. PubMed ID: 26330419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
    Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
    Kerkmeijer LSM; Renkens MPL; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Garcia-Garcia HM; Kraak R; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2022 Mar; 17(16):1340-1347. PubMed ID: 34483094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.